A university research group asked our consultants to develop a plan for commercialising a novel drug delivery technology.
Our consultants were asked to validate a novel drug delivery technology by modelling the performance of a product based on the technology by reference to the literature and the performance of commercially available products. They were then asked to develop a plan for designing and developing a product based on the technology through to CE marking. This included: the medical device design and development plan; human factor studies; a process for manufacture; an analysis of the bill of materials and manufacturing costs; safety studies and testing requirements for CE marking. This was done in compliance with ISO 13485. The technology was shown to be the potential foundation for a high performance product that delivered drugs more efficiently to the lungs to treat both local and systemic diseases, was more convenient for patients, and added no cost over more conventional products. This plan will be used to raise funding to commercialise the technology.
We are a specialist medical device consultancy consisting of industry experts with long and successful track records in commercialising medical device products. We have broad functional and sector experience, and would welcome an opportunity to discuss with you any challenge relating to creating sustainable value from medical technologies.
Munna Choudhury of Alacramed will be attending UK BIOTECH SUMMIT 2019, on
Mark Wickham of Alacramed will be attending Med-Tech Innovation Expo 2019 at
We understand the need for accurate, tailored health economic and budget impact
Alacramed Ltd, St Johns Innovation Centre, Cowley Road, Cambridge,
+44 (0) 1223 421885